Blood vessels in the anterior region of the knee joint of anaesthetised rabbits showed a biphasic response to the electrical stimulation (10 Hz, 1 ms width, 10 V amplitude) of nerve fibres supplying the knee, as measured by laser Doppler flowmetry. The response consisted of vasoconstriction during nerve stimulation followed by a prolonged dilatation. The vasoconstrictor response was mediated by noradrenaline acting mainly via α1-adrenoceptors as it was substantially reduced by close intra-arterial injection of the α-adrenergic antagonist phentolamine (∼50% reduction) and the selective α1-adrenergic antagonist prazosin (∼50% reduction) but not by the α2-antagonist rauwolscine. Further studies involving prolonged (2-hour) close intra-arterial infusion of prazosin gave a ∼ 50% reduction of the constrictor response with a concentration of 10-5M and ∼95% reduction when the concentration was raised to 10-4M. At the higher prazosin concentration responses to close intra-arterial injection of the α1-agonist phenylephrine were substantially reduced but responses to the α2-agonists clonidine and UK-14304 were not significantly influenced. Infusions of the α2 antagonist CH 38083 failed to inhibit nerve-mediated vasoconstriction at 10-5 or 10-4M. There did not appear to be a purinergic component, as the constrictor response was unaffected by the P2x desensitiser αβ-methylene adenosine 5’-triphosphate. The dilator response appeared to be mediated principally by substance P (presumably released from sensory C fibers) as it was substantially reduced by intra-articular injection of substance P antagonist D-Pro4D-Trp7,9,10-SP(4-ll). These results indicate that in the anterior region of the rabbit knee joint α- adrenoceptors mediate vasoconstriction during electrical stimulation of the nerve supply to joint blood vessels and suggest that the neurotransmitter is likely to be noradrenaline. The dilator response may arise from activation of sensory (C) nerve fibres containing substance P which could have a patho-physiological role in inflammatory joint disease.

Keywords:
Blood flow, Joint, Adrenoceptor, Nerve stimulation
This content is only available via PDF.
© 1993 S. Karger AG, Basel
1993
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.